# Dermatologic Therapy

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/dermatologic-therapy/

## Facts

| Field | Value |
| --- | --- |
| Open Access | false |
| ISSN-L | 1396-0296 |
| ISSNs | 1396-0296,1529-8019 |
| OpenAlex ID | https://openalex.org/S67424211 |
| Publisher | Wiley |

## Journal papers

- [Adherence to Mediterranean diet in Spanish patients with psoriasis: Cardiovascular benefits?](https://scholariq.org/papers/adherence-to-mediterranean-diet-in-spanish-patients-with-psoriasis/)
- [Chilblain‐like lesions in pediatrics dermatological outpatients during the <scp>COVID</scp> ‐19 outbreak](https://scholariq.org/papers/chilblain-like-lesions-in-pediatrics-dermatological-outpatients-during-the-scp/)
- [Maculopapular eruptions associated to <scp>COVID</scp> ‐19: A subanalysis of the <scp>COVID‐Piel</scp> study](https://scholariq.org/papers/maculopapular-eruptions-associated-to-scp-covid-scp-19-a-subanalysis-of-the-scp/)
- [Drug survival of ixekizumab, TNF inhibitors, and other IL‐17 inhibitors in real‐world patients with psoriasis: The Corrona Psoriasis Registry](https://scholariq.org/papers/drug-survival-of-ixekizumab-tnf-inhibitors-and-other-il-17-inhibitors-in-real/)
- [Fifty‐two week follow‐up safety and effectiveness results of dupilumab treatment of moderate‐to‐severe atopic dermatitis from a retrospective, multicentric series](https://scholariq.org/papers/fifty-two-week-follow-up-safety-and-effectiveness-results-of-dupilumab-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.